Small Interfering RNA (siRNA) Therapeutics Market Size, Share & Trends Analysis Report By Delivery (Lipid Nanoparticles (LNPs), Conjugates), by Indication (Hereditary Transthyretin-mediated Amyloidosis, Acute Hepatic Porphyria, Primary Hyperoxaluria Type 1, Primary Hypercholesterolemia, Others), by RoA (Intravenous (IV), Subcutaneous), By Region, And By Segment Forecasts, 2024-2031

Report Id: 2629 Pages: 178 Last Updated: 30 May 2025 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Segmentation of Small Interfering RNA (siRNA) Therapeutics Market-

Small Interfering RNA (siRNA) Therapeutics Market By Product Type-

  • Onpattro (Patisiran)
  • Givlaari (Givosiran)
  • Oxlumo (Lumasiran)
  • Leqvio (Inclisiran)
  • Amvuttra (Vutrisiran)
  • Rivfloza (Nedosiran)
  • Wainua (Eplontersen)
  • Others

 siRNA

Small Interfering RNA (siRNA) Therapeutics Market By Delivery Methods-

  • Lipid Nanoparticles (LNPs)
  • GalNAc-Conjugates
  • Other Delivery Systems

Small Interfering RNA (siRNA) Therapeutics Market By Indication-

  • Hereditary Transthyretin-Mediated Amyloidosis (hATTR)
  • Acute Hepatic Porphyria (AHP)
  • Primary Hyperoxaluria Type 1 (PH1)
  • Primary Hypercholesterolemia
  • Other (Oncology, Viral Infections, Neurodegenerative Diseases)

Small Interfering RNA (siRNA) Therapeutics Market By RoA-

  • Intravenous (IV)
  • Subcutaneous 

Small Interfering RNA (siRNA) Therapeutics Market By End-User-

  • Hospitals and Clinics
  • Research Institutions
  • Pharmaceutical and Biotechnology Companies
  • Academic Institutions

Small Interfering RNA (siRNA) Therapeutics Market By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Small Interfering RNA (siRNA) Therapeutics Market Snapshot

Chapter 4. Global Small Interfering RNA (siRNA) Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2025-2034
4.8. Global Small Interfering RNA (siRNA) Therapeutics Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2024)

Chapter 5. Small Interfering RNA (siRNA) Therapeutics Market Segmentation 1: By Product Type, Estimates & Trend Analysis
5.1. Market Share by Product Type, 2024 & 2034
5.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Product Type:

5.2.1. Onpattro (Patisiran)
5.2.2. Givlaari (Givosiran)
5.2.3. Oxlumo (Lumasiran)
5.2.4. Leqvio (Inclisiran)
5.2.5. Amvuttra (Vutrisiran)
5.2.6. Rivfloza (Nedosiran)
5.2.7. Wainua (Eplontersen)
5.2.8. Others

Chapter 6. Small Interfering RNA (siRNA) Therapeutics Market Segmentation 2: By Delivery Method, Estimates & Trend Analysis
6.1. Market Share by Delivery Method, 2024 & 2034
6.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Delivery Method:

6.2.1. Lipid Nanoparticles (LNPs)
6.2.2. GalNAc-Conjugates
6.2.3. Other Delivery Systems

Chapter 7. Small Interfering RNA (siRNA) Therapeutics Market Segmentation 3: By Indication,
Estimates & Trend Analysis
7.1. Market Share by Indication, 2024 & 2034
7.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following Indication:

7.2.1. Hereditary Transthyretin-mediated Amyloidosis
7.2.2. Acute Hepatic Porphyria
7.2.3. Primary Hyperoxaluria Delivery 1
7.2.4. Primary Hypercholesterolemia
7.2.5. Others

Chapter 8. Small Interfering RNA (siRNA) Therapeutics Market Segmentation 4: By RoA, Estimates & Trend Analysis
8.1. Market Share by RoA, 2024 & 2034
8.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following RoA:

8.2.1. Intravenous (IV)
8.2.2. Subcutaneous

Chapter 9. Small Interfering RNA (siRNA) Therapeutics Market Segmentation 5: By End-user, Estimates & Trend Analysis
9.1. Market Share by End-user, 2024 & 2034
9.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following End-user:

9.2.1. Hospitals and Clinics
9.2.2. Research Institutions
9.2.3. Pharmaceutical and Biotechnology Companies
9.2.4. Academic Institutions

Chapter 10. Small Interfering RNA (siRNA) Therapeutics Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. Global Small Interfering RNA (siRNA) Therapeutics Market, Regional Snapshot 2024 & 2034

10.2. North America
10.2.1. North America Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
10.2.1.1. US
10.2.1.2. Canada
10.2.2. North America Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Product Type, 2021-2034
10.2.3. North America Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Delivery Method, 2021-2034
10.2.4. North America Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Indication, 2021-2034
10.2.5. North America Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by RoA, 2021-2034
10.2.6. North America Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by End-user, 2021-2034

10.3. Europe
10.3.1. Europe Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
10.3.1.1. Germany
10.3.1.2. U.K.
10.3.1.3. France
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. Rest of Europe
10.3.2. Europe Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Product Type, 2021-2034
10.3.3. Europe Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Delivery Method, 2021-2034
10.3.4. Europe Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Indication, 2021-2034
10.3.5. Europe Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by RoA, 2021-2034
10.3.6. Europe Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by End-user, 2021-2034

10.4. Asia Pacific
10.4.1. Asia Pacific Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
10.4.1.1. India
10.4.1.2. China
10.4.1.3. Japan
10.4.1.4. Australia
10.4.1.5. South Korea
10.4.1.6. Hong Kong
10.4.1.7. Southeast Asia
10.4.1.8. Rest of Asia Pacific
10.4.2. Asia Pacific Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Product Type, 2021-2034
10.4.3. Asia Pacific Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Delivery Method, 2021-2034
10.4.4. Asia Pacific Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Indication, 2021-2034
10.4.5. Asia Pacific Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by RoA, 2021-2034
10.4.6. Asia Pacific Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by End-user, 2021-2034

10.5. Latin America
10.5.1. Latin America Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Country, 2021-2034
10.5.1.1. Brazil
10.5.1.2. Mexico
10.5.1.3. Rest of Latin America
10.5.2. Latin America Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Product Type, 2021-2034
10.5.3. Latin America Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Delivery Method, 2021-2034
10.5.4. Latin America Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Indication, 2021-2034
10.5.5. Latin America Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by RoA, 2021-2034
10.5.6. Latin America Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by End-user, 2021-2034

10.6. Middle East & Africa
10.6.1. Middle East & Africa Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by country, 2021-2034
10.6.1.1. GCC Countries
10.6.1.2. Israel
10.6.1.3. South Africa
10.6.1.4. Rest of Middle East and Africa
10.6.2. Middle East & Africa Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Product Type, 2021-2034
10.6.3. Middle East & Africa Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Delivery Method, 2021-2034
10.6.4. Middle East & Africa Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by Indication, 2021-2034
10.6.5. Middle East & Africa Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by RoA, 2021-2034
10.6.6. Middle East & Africa Small Interfering RNA (siRNA) Therapeutics Market Revenue (US$ Mn) Estimates and Forecasts by End-user, 2021-2034

Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances

11.2. Company Profiles
11.2.1. Companies with Approved Products:

11.2.1.1. Alnylam Pharmaceuticals
11.2.1.2. Novartis
11.2.1.3. Dicerna Pharmaceuticals (Novo Nordisk)
11.2.1.4. Ionis Pharmaceuticals
11.2.1.5. AstraZeneca

11.2.2. In Clinical Trials:

11.2.2.1. Arrowhead Pharmaceuticals
11.2.2.2. Silence Therapeutics
11.2.2.3. Wave Life Sciences
11.2.2.4. Sirnaomics
11.2.2.5. Sylentis S.A.
11.2.2.6. Quark Pharmaceuticals
11.2.2.7. Arbutus Biopharma
11.2.2.8. Phio Pharmaceuticals
11.2.2.9. Benitec Biopharma
11.2.2.10. Bio-Path Holdings

11.2.3. Companies With Delivery Platforms:

11.2.3.1. ABL Bio
11.2.3.2. Arbutus Biopharma
11.2.3.3. Calando Pharmaceuticals
11.2.3.4. Genecon Biotechnologies

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
6481
Security Code field cannot be blank!

Frequently Asked Questions

The Small Interfering RNA (siRNA) Therapeutics Market Size is valued at USD 1.6 Bn in 2023 and is predicted to reach USD 4.89 Bn by the year 2031

The Small Interfering RNA (siRNA) Therapeutics Market is expected to grow at a 15.0% CAGR during the forecast period for 2024-2031.

Alnylam, Silence Therapeutics, Silenseed Ltd, Sylentis, S.A., Sanofi Genzyme, Quark Pharmaceuticals, Dicerna Pharmaceuticals, Arrowhead Pharmaceutical

Report License Selection

Determine the Appropriate License for your Report

Get Sample Report Enquiry Before Buying